Project Grant R41AI122441

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation for occidiofungin and conduct the necessary toxicological and stability studies to support an Investigational...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $170,000.00 to Prokaryotics Incorporated to support research and development of a novel antifungal agent that inhibits the glycosylphosphatidylinositol (GPI) biosynthesis pathway in fungal pathogens. The key goals of this 2-year project are to: 1) Perform cryo-EM structural studies to elucidate the molecular interactions between the lead...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $642,775 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis to accelerate the discovery of new antifungal peptides using one-bead one-compound (OBOC) combinatorial technology. The research aims to rapidly develop and optimize novel broad-spectrum antifungal agents with defined physicochemical properties, diverse mechanisms of action, and a high...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,421,153 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of Colorado to develop novel antifungal agents against coccidioidomycosis, a serious fungal infection endemic to the Southwestern United States. The overarching goal of this 5-year collaborative project is to optimize the antifungal activity of synthetic analogs as a potential lead for treating Valley...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Microrid Technologies Inc. located in Dix Hills, NY. The goal of this 1-year project is to discover and develop new antifungal therapeutics that target the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth and survival in host environments. The researchers will screen compound libraries to...

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $308,925 to Chemia Biosciences, Inc. to develop computational methods and software tools for discovering novel natural products from fungal species. The project aims to leverage high-throughput mass spectrometry and genome mining techniques to identify new molecular compounds with potential antibiotic and therapeutic...

This $325,000 Project Grant awarded by the USDA National Institute of Food and Agriculture (NIFA) under the Crop Protection and Pest Management (CPPM) Competitive Grants Program (CFDA 10.329) will fund a three-year research project at the University of California, Davis (UC Davis) to address fungicide resistance in the fungal pathogen Botrytis cinerea, which causes significant economic losses for fruit, ornamental, vegetable, and sugar beet crops in California and Michigan. The key objectives...

The University of Iowa was awarded a Project Grant of $443,175 by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to develop a high-throughput screening assay to identify novel antifungal compounds active against the mold Aspergillus fumigatus. This grant aims to address the high mortality rates and increasing resistance to current antifungal treatments for invasive mold infections, which primarily impact immunocompromised...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Clue Genetics Inc. for the development of a fungi-focused metabologenomics platform for natural product discovery. The key products and services to be delivered under this 1-year Phase I SBIR project include: Annotating biosynthetic gene clusters (BGCs) from 200 genomes selected from a diverse set of bioactive fungi to uncover new drugs,...